Cite

HARVARD Citation

    Muto, Y. et al. (2018). Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis. Melanoma research. 28 (2), p. . [Online]. 
  
Back to record